Dextroamphetamine as an Adjunct in Cocaine Treatment - 1
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders; Substance-Related Disorders
Intervention: Dextroamphetamine (Drug); D-Amphetamine (Drug); Placebo (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s): John Grabowski, Ph.D., Principal Investigator, Affiliation: University of Texas
Summary
The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an
adjunct in cocaine treatment; an evaluation of the ""replacement"" strategy.
Clinical Details
Official title: Dextroamphetamine as an Adjunct in Cocaine Treatment
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: verifiable cocaine abstinence
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Please contact site for information.
Locations and Contacts
University of Texas Health Science Center, Houston, Texas 77225, United States
Additional Information
Starting date: August 1997
Last updated: August 14, 2008
|